[Expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance].
to investigate the expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance. the levels of serum MIF were measured by an enzyme linked immunosorbent assay (ELISA) in 36 patients with prostate cancer, 32 patients with benign prostatic hyperplasia (BPH) and 20 healthy male adults as healthy controls. the MIF levels of patients with prostate cancer were significantly higher than those of the other two groups (p<0.05). The level of MIF was found to relate to the clinical stages and Gleason scores of prostate cancer (P<0.05). MIF may play an important role in the oncogenesis and development of prostate cancer. The serum MIF level can be useful as a novel biomarker for the detection of prostate cancer as well as a predictor of disease progression.